



March 17, 2016

## Foundation Medicine Announces Presentations at the AACR Annual Meeting 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Foundation Medicine, Inc.](http://www.foundationmedicine.com) (NASDAQ:FMI) today announced that the company and its collaborators will present two mini-symposium presentations and seven posters at the American Association for Cancer Research (AACR) Annual Meeting 2016 taking place April 16-20 in New Orleans.

The company's molecular information products, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer. The data to be presented at AACR add to an ever-increasing body of evidence supporting the benefits of comprehensive genomic profiling in cancer care.

The schedule for *mini-symposium presentations* by Foundation Medicine and/or its collaborators is as follows:

**Date and Time:** Monday, April 18, 2016 from 3:35 p.m. to 3:50 p.m.

**Title:** The landscape of tumor mutation load across the entire spectrum of human cancer derived from 60,000 patients

**Abstract Number:** 2629

**Location:** Room 260, Morial Convention Center

**Session:** Genomic Landscapes

**Presenter:** Garrett Frampton, Ph.D., associate director, bioinformatics, Foundation Medicine

**Date and Time:** Tuesday, April 19, 2016 from 3:20 p.m. to 3:35 p.m.

**Title:** Activation mechanism of oncogenic C-helix shifting mutations in BRAF, EGFR, and HER2

**Abstract Number:** 4374

**Location:** Room 354, Morial Convention Center

**Session:** Oncogenic Cell Signaling: Mechanisms and Translational Insight

**Presenter:** Scott Foster, Ph.D., postdoctoral fellow, Genentech

**Collaborator:** Genentech

The schedule for *poster presentations* by Foundation Medicine and/or its collaborators is as follows:

**Date and Time:** Monday, April 18, 2016 from 8:00 a.m. to 12:00 p.m.

**Title:** Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis

**Abstract Number:** 1144

**Poster Board Number:** 24

**Poster Display Location:** Section 8

**Session:** Oncogene Function, Regulation, and Targeting

**Presenter:** Kazuhiko Shien, Ph.D., postdoctoral fellow, MD Anderson Cancer Center

**Collaborators:** MD Anderson Cancer Center, Yale Cancer Center

**Date and Time:** Monday, April 18, 2016 from 1:00 p.m. to 5:00 p.m.

**Title:** Enrichment of targetable mutations in the relapsed neuroblastoma genome

**Abstract Number:** 2431

**Poster Board Number:** 8

**Poster Display Location:** Section 30

**Session:** Pediatric Cancer Genomics, Genetics, and Epigenetics

**Presenter:** Olivia Padovan-Merhar, Ph.D., postdoctoral fellow, Children's Hospital of Philadelphia

**Collaborators:** Children's Hospital of Philadelphia, Cook Children's Healthcare System, Memorial Sloan Kettering Cancer Center

**Date and Time:** Monday, April 18, 2016 from 1:00 p.m. to 5:00 p.m.

**Title:** Genomic profiling of 1239 diverse pediatric cancers identifies novel discoveries across tumors

**Abstract Number:** LB-178

**Poster Board Number:** 4

**Poster Display Location:** Section 11

**Session:** Late-Breaking Research: Tumor Biology 2

**Presenter:** Juliann Chmielecki, Ph.D., associate director, cancer genomics, Foundation Medicine

**Date and Time:** Tuesday, April 19, 2016 from 8:00 a.m. to 12:00 p.m.

**Title:** Delivery of point-of-care management to patients with gynecologic malignancies using comprehensive genomic profiling

**Abstract Number:** 3183

**Poster Board Number:** 20

**Poster Display Location:** Section 23

**Session:** Molecular Classification and Genomic Applications

**Presenter:** Lorna Rodriguez, M.D., Ph.D., director, precision medicine initiative, gynecologic oncologist, Rutgers Cancer Institute of New Jersey

**Collaborators:** Rutgers Cancer Institute of New Jersey, Rutgers Wood Johnson Medical School

**Date and Time:** Tuesday, April 19, 2016 from 1:00 p.m. to 5:00 p.m.

**Title:** Rigorous validation of a clinical circulating tumor DNA assay for cancer molecular profiling

**Abstract Number:** 3965

**Poster Board Number:** 25

**Poster Display Location:** Section 23

**Session:** Circulating Biomarkers 3 / Immune Biomarkers

**Presenter:** Travis Clark Ph.D., senior scientist, R&D, Foundation Medicine; Mark Kennedy Ph.D., principal computational biologist, Foundation Medicine

**Collaborator:** Genentech

**Date and Time:** Tuesday, April 19, 2016 from 1:00 p.m. to 5:00 p.m.

**Title:** Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load

**Abstract Number:** 3576

**Poster Board Number:** 1

**Poster Display Location:** Section 5

**Session:** Genetic Instability in Cancer: Molecular Basis and Tools

**Presenter:** Zachary Chalmers, senior research associate, Foundation Medicine

**Collaborator:** Dana-Farber Cancer Institute

**Date and Time:** Wednesday, April 20, 2016 from 8:00 a.m. to 12:00 p.m.

**Title:** Subtypes of urothelial carcinoma of the urinary bladder defined by genomic alteration combinations predict clinical characteristics

**Abstract Number:** LB-328

**Poster Board Number:** 23

**Poster Display Location:** Section 10

**Session:** Late-Breaking Research: Molecular and Cellular Biology 3

**Presenter:** Alyna Khan, knowledge analyst, Foundation Medicine

## About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit <http://www.FoundationMedicine.com> or follow Foundation Medicine on Twitter (@FoundationATCG).

*Foundation Medicine®*, *FoundationOne®*, and *FoundationOne® Heme* are registered trademarks of Foundation Medicine, Inc.

## Cautionary Note Regarding Forward-Looking Statements

*This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits of comprehensive genomic profiling, including*

*FoundationOne and FoundationOne Heme in cancer care. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.*

View source version on [businesswire.com](http://www.businesswire.com/news/home/20160317005167/en/): <http://www.businesswire.com/news/home/20160317005167/en/>

**Media Contact:**

Pure Communications, Inc.  
Dan Budwick, 973-271-6085  
[dan@purecommunicationsinc.com](mailto:dan@purecommunicationsinc.com)

**or**

**Investor Contact:**

Foundation Medicine  
Kimberly Brown, 617-418-2215  
[ir@foundationmedicine.com](mailto:ir@foundationmedicine.com)

**or**

Pure Communications, Inc.  
Matt Clawson, 949-370-8500  
[matt@purecommunicationsinc.com](mailto:matt@purecommunicationsinc.com)

Source: Foundation Medicine, Inc.

News Provided by Acquire Media